Irene M. Ghobrial

Jan 24, 2025 | nature.com | Irene M. Ghobrial

Recent results from the phase III AQUILA trial demonstrate the benefit of fixed-duration monotherapy with daratumumab over observation in patients with high-risk smouldering multiple myeloma, which changes the early interception treatment landscape. Herein, we discuss how future studies could build on this success and pave the way to eradicating multiple myeloma before it starts.

May 8, 2024 | nature.com | Franco Izzo |Robert Myers |Levan Mekerishvili |Elliot Eton |Eleni P. Mimitou |Daniel Choi | +6 more

AbstractIn somatic tissue differentiation, chromatin accessibility changes govern priming and precursor commitment towards cellular fates1,2,3. Therefore, somatic mutations are likely to alter chromatin accessibility patterns, as they disrupt differentiation topologies leading to abnormal clonal outgrowth. However, defining the impact of somatic mutations on the epigenome in human samples is challenging due to admixed mutated and wild-type cells.

Aug 10, 2023 | nature.com | Wencong Wang |Irene M. Ghobrial

Correction to: Nature Nanotechnology https://doi.org/10.1038/s41565-022-01310-1. Published online 26 January 2023.